↓ Skip to main content

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME®…

Overview of attention for article published in Diabetologia, May 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
102 X users
facebook
1 Facebook page

Citations

dimensions_citation
90 Dimensions

Readers on

mendeley
227 Mendeley